Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 28, 2015; 7(6): 910-915
Published online Apr 28, 2015. doi: 10.4254/wjh.v7.i6.910
Published online Apr 28, 2015. doi: 10.4254/wjh.v7.i6.910
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy
Chantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, Cindy Neuzillet, Eric Raymond, Sandrine Faivre, Department of Medical Oncology, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 92110 Clichy, France
Mohamed Bouattour, Department of Hepatology, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 92110 Clichy, France
Maxime Ronot, Department of Imaging, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 92110 Clichy, France
Safi Dokmak, Jacques Belghiti, Department of Biliary and Pancreatic Surgery, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 92110 Clichy, France
Nathalie Guedj, Valérie Paradis, Department of Pathology, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 92110 Clichy, France
Author contributions: Dreyer C, Belghiti J, Raymond E and Faivre S conceived and designed the study; Dreyer C, Dokmak S, Belghiti J, Guedj N, Paradis V and Faivre S provided study materials of patients; Dreyer C, Sablin MP, Bouattour M and Faivre S collected and assembled data; Dreyer C, Sablin MP, Bouattour M, Raymond E and Faivre S analyzed and interpreted data; Ronot M and Faivre S participated in the acquisition and interpretation of radiological figures; all authors participated in manuscript written; all authors give final approval of manuscript.
Supported by Pfizer Inc, funding ACUMED (Tytherington, UK) for manuscript editing.
Ethics approval: The Ethics approval is not mandatory in France for individual compassionate use of a drug that has been approved in another indication.
Informed consent: An individual consent has been obtained from each patient regarding the off-label use of sunitinib in cholangiocarcinoma.
Conflict-of-interest: Eric Raymond and Sandrine Faivre have received honoraria from Pfizer. All other authors have no disclosures to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Mohamed Bouattour, Department of Medical Oncology and Hepatology, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 100 boulevard du Général Leclerc, 92110 Clichy, France. mohamed.bouattour@bjn.aphp.fr
Telephone: +33-1-40875525 Fax: +33-1-40875487
Received: September 2, 2014
Peer-review started: September 2, 2014
First decision: November 27, 2014
Revised: January 10, 2015
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: April 28, 2015
Peer-review started: September 2, 2014
First decision: November 27, 2014
Revised: January 10, 2015
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: April 28, 2015
Core Tip
Core tip: No systemic therapy after progression on platinum-based chemotherapy is currently approved. Based on imaging hypervascular pattern and molecular expression of vascular endothelial growth factor, we evaluated sunitinib, a multikinase inhibitor as second line treatment in patients with advanced intrahepatic cholangiocarcinoma. We report 3 cases of disease control lasting 4-16 mo that provide the rational for developing prospective clinical trials with sunitinib in second line for advanced intrahepatic cholangiocarcinoma.